GOSS Valuation

Gossamer Bio Inc

Add to Watchlist

Advanced Chart

1.970

+0.01(0.510%)1D

Overview
Forecast
Valuation
Earnings

GOSS Relative Valuation

GOSS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GOSS is overvalued; if below, it's undervalued.

Historical Valuation

Gossamer Bio Inc (GOSS) is now in the Overvalued zone, suggesting that its current forward PS ratio of 17.12 is considered Overvalued compared with the five-year average of -2.48. The fair price of Gossamer Bio Inc (GOSS) is between 1.37 to 1.96 according to relative valuation methord. Compared to the current price of 1.97 USD , Gossamer Bio Inc is Overvalued By 0.27%.

Relative Value

Fair Zone

1.37-1.96

Current Price：1.97

0.27%

Overvalued

-2.90

Trailing

Forward

-4.77

EV/EBITDA

Gossamer Bio Inc. (GOSS) has a current EV/EBITDA of -4.77. The 5-year average EV/EBITDA is -1.92. The thresholds are as follows: Strongly Undervalued below -4.67, Undervalued between -4.67 and -3.29, Fairly Valued between -0.54 and -3.29, Overvalued between -0.54 and 0.83, and Strongly Overvalued above 0.83. The current Forward EV/EBITDA of -4.77 falls within the Strongly Undervalued range.

-2.48

EV/EBIT

Gossamer Bio Inc. (GOSS) has a current EV/EBIT of -2.48. The 5-year average EV/EBIT is -1.72. The thresholds are as follows: Strongly Undervalued below -4.26, Undervalued between -4.26 and -2.99, Fairly Valued between -0.46 and -2.99, Overvalued between -0.46 and 0.81, and Strongly Overvalued above 0.81. The current Forward EV/EBIT of -2.48 falls within the Historic Trend Line -Fairly Valued range.

17.12

Gossamer Bio Inc. (GOSS) has a current PS of 17.12. The 5-year average PS is 22.40. The thresholds are as follows: Strongly Undervalued below -146.25, Undervalued between -146.25 and -61.93, Fairly Valued between 106.72 and -61.93, Overvalued between 106.72 and 191.04, and Strongly Overvalued above 191.04. The current Forward PS of 17.12 falls within the Historic Trend Line -Fairly Valued range.

-4.99

P/OCF

Gossamer Bio Inc. (GOSS) has a current P/OCF of -4.99. The 5-year average P/OCF is 57.44. The thresholds are as follows: Strongly Undervalued below -491.42, Undervalued between -491.42 and -216.99, Fairly Valued between 331.87 and -216.99, Overvalued between 331.87 and 606.30, and Strongly Overvalued above 606.30. The current Forward P/OCF of -4.99 falls within the Historic Trend Line -Fairly Valued range.

-4.91

P/FCF

Gossamer Bio Inc. (GOSS) has a current P/FCF of -4.91. The 5-year average P/FCF is -43.77. The thresholds are as follows: Strongly Undervalued below -407.27, Undervalued between -407.27 and -225.52, Fairly Valued between 137.99 and -225.52, Overvalued between 137.99 and 319.74, and Strongly Overvalued above 319.74. The current Forward P/FCF of -4.91 falls within the Historic Trend Line -Fairly Valued range.

Gossamer Bio Inc (GOSS) has a current Price-to-Book (P/B) ratio of -9.66. Compared to its 3-year average P/B ratio of -2.24 , the current P/B ratio is approximately 331.86% higher. Relative to its 5-year average P/B ratio of -0.72, the current P/B ratio is about 1241.99% higher. Gossamer Bio Inc (GOSS) has a Forward Free Cash Flow (FCF) yield of approximately -34.64%. Compared to its 3-year average FCF yield of -58.32%, the current FCF yield is approximately -40.60% lower. Relative to its 5-year average FCF yield of -45.19% , the current FCF yield is about -23.35% lower.

-9.66

P/B

Median3y

-2.24

Median5y

-0.72

-34.64

FCF Yield

Median3y

-58.32

Median5y

-45.19

Competitors Valuation Multiple

The average P/S ratio for GOSS's competitors is 20.17, providing a benchmark for relative valuation. Gossamer Bio Inc Corp (GOSS) exhibits a P/S ratio of 17.12, which is -15.12% above the industry average. Given its robust revenue growth of -88.01%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Tonix Pharmaceuticals Holding Corp

Lexicon Pharmaceuticals Inc

Cullinan Therapeutics Inc

Performance Decomposition

Market capitalization of GOSS increased by 123.23% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -0.30 to -3.20.

The secondary factor is the Revenue Growth, contributed -88.01%to the performance.

Overall, the performance of GOSS in the past 1 year is driven by P/E Change. Which is more unsustainable.

-88.01%

95.84M → 11.49M

Revenue Growth

-748.49%

51.37 → -333.13

Margin Expansion

959.73%

-0.30 → -3.20

P/E Change

123.23%